Despite the utilization of agents such as vascular endothelial growth factor (VEGF) inhibitors, mammalian target of rapamycin (mTOR) inhibitors, and RAF kinase inhibitors in RCC treatment, the clinical application of these drugs often encounters the challenge of drug resistance [8]. This evidence concerns the gene VEGFA and renal cell carcinoma.